Compare International Business Machines Corp (IBM) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
International Business Machines Corp vs TG Therapeutics Inc — how do they compare? International Business Machines Corp trades at $226.99 (market cap $213.50B), while TG Therapeutics Inc trades at $55.11 (market cap $8.16B). The key difference: International Business Machines Corp is far larger — about 26.2× TG Therapeutics Inc's market cap, and International Business Machines Corp pays a 2.98% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold International Business Machines Corp for 88 Days and TG Therapeutics Inc for 16 Days on average.
| IBM | TGTX | |
|---|---|---|
Market Cap | $213.50B | $8.16B |
Volume | 8,908,687 | 1,735,121 |
Sector | Technology | Health |
52-Week High | $329.23 | $59.06 |
52-Week Low | $205.77 | $26.94 |
Typical Hold Time | 88 Days | 16 Days |
Enterprise Value | $270.64B | $8.37B |
Dividend Yield | 2.98% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IBM stock trades at $227.13, up 3.0% today, showing resilience after recent volatility. The company reported strong Q4 2025 and Q1 2026 earnings beats but missed Q2 2026 expectations. Revenue growth accelerated to $67.54B in 2025 with net income margin improving to 15.52%. Technical indicators show bearish momentum with RSI at 71.56 suggesting overbought conditions, while analyst consensus remains positive with a $255.50 price target.
IBM's pivot to hybrid cloud and AI consulting shows promise with $5.5B generative AI bookings, though execution risks persist. The stock offers 12.5% upside to consensus target but faces headwinds from mainframe cyclicality and competitive pressure. Cash flow trends weakened in 2025 with negative net cash flow, requiring monitoring of capital allocation strategy.
TG Therapeutics (TGTX) trades at $54.80, up 3.49% today, but faces a bearish technical signal with recent earnings misses. Revenue growth is strong, with 2026 guidance raised to $950M for BRIUMVI, and net income margins exceed 55%. However, cash flow was negative in 2025, and a shareholder litigation investigation adds near-term uncertainty.
The outlook is mixed: analyst consensus is bullish with an $80.50 price target, but execution risks and earnings volatility persist. Upside hinges on BRIUMVI market share gains and subcutaneous formulation progress, while legal and competitive pressures pose threats to shareholder value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About International Business Machines Corp
International Business Machines Corporation (IBM) provides computer solutions. The Company offers application, technology consulting and support, process design and operations, cloud, digital workplace, and network services, as well as business resiliency, strategy, and design solutions. IBM serves clients worldwide.
Read more on IBM →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
